PharmaCorp Refiles Q2 2025 Financial Statements
SASKATOON, Saskatchewan, Oct. 10, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. ("PharmaCorp" or the "Corporation") (TSXV: PCRX) has restated and refiled its financial statements for the interim period ended June 30, 2025 (the "Amended Q2 2025 Statements") as we
(Financial Post, 2025-10-10T23:59:33Z)